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Parly Ultrafiltration in Patients With
ecompensated Heart Failure and Diuretic Resistance
aria Rosa Costanzo, MD, FACC,* Mitchell Saltzberg, MD, FACC,* Jeanne O’Sullivan, RN,*
aul Sobotka, MD, FACC†
ombard, Illinois; and Brooklyn Park, Minnesota
OBJECTIVES We sought to determine if ultrafiltration before intravenous (IV) diuretics in patients with
decompensated heart failure and diuretic resistance results in euvolemia and early discharge
without hypotension or worsening renal function.
BACKGROUND Heart failure patients with renal insufficiency and diuretic resistance have increased hospital
mortality and length of stay. Peripheral veno-venous ultrafiltration may re-establish euvol-
emia and diuretic responsiveness.
METHODS Ultrafiltration was initiated within 4.7  3.5 h of hospitalization and before IV diuretics in
20 heart failure patients with volume overload and diuretic resistance (age 74.5  8.2 years;
75% ischemic disease; ejection fraction 31  15%) and continued until euvolemia. Re-
evaluation was each hospital day, at 30 days, and at 90 days.
RESULTS A total of 8,654  4,205 ml were removed with ultrafiltration. Twelve patients (60%) were
discharged in 3 days. One patient was readmitted in 30 days. Weight (p  0.006),
Minnesota Living with Heart Failure scores (p  0.003), and Global Assessment (p 
0.00003) improved after ultrafiltration and at 30 and 90 days. Median B-type natriuretic
peptide levels decreased after ultrafiltration (from 1,230 pg/ml to 788 pg/ml) and at 30 days
(815 pg/ml) (p  0.035). Blood pressure, renal function, and medications were unchanged.
CONCLUSIONS In heart failure patients with volume overload and diuretic resistance, ultrafiltration before IV
diuretics effectively and safely decreases length of stay and readmissions. Clinical benefits
persist at three months. (J Am Coll Cardiol 2005;46:2047–51) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.099College of Cardiology Foundation
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2raditional diuretic therapy for congestion in acute decom-
ensated heart failure (ADHF) is often ineffective and
xpensive. The Acute Decompensated Heart Failure Na-
ional Registry (ADHERE) shows that most ADHF hos-
italizations are due to congestion in patients refractory to
ral diuretics (1). Despite use of intravenous diuretics in
See page 2052
0% of patients, the average hospitalization for ADHF is
.3 days, with 42% of the patients discharged with unre-
olved symptoms, 50% losing 5 pounds, and 20% gaining
eight during the hospitalization (1). Unresolved conges-
ion may contribute to high readmission rates (1).
Approximately 25% to 30% of patients develop diuretic
esistance, defined as reduced diuresis and natriuresis (2).
herapies for diuretic resistance have limited success (3).
enal insufficiency and diuretic resistance are associated
ith prolonged hospitalization (4,5). Even mild renal in-
ufficiency in patients with left ventricular systolic dysfunc-
ion independently predicts morbidity and mortality (6).
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Manuscript received February 18, 2005; revised manuscript received May 4, 2005,
ccepted May 10, 2005.ntravenous diuretics can increase pulmonary capillary
edge pressure and systemic vascular resistance and reduce
ardiac output and glomerular filtration rate (7,8).
Ultrafiltration is an alternative treatment that has been
hown to reduce right atrial and pulmonary artery wedge
ressures and increase cardiac output, diuresis, and natri-
resis without changes in heart rate, systolic blood pressure
SBP), renal function, electrolytes, or intravascular volume
9). Neurohormones drop below control values in the
ltrafiltration- but not in the diuretic-treated patients,
xplaining why ultrafiltration benefits last for three months
9). Recently, the safety and efficacy of peripheral ultrafil-
ration was demonstrated in fluid-overloaded patients (10).
We sought to determine if early ultrafiltration in ADHF
atients with diuretic resistance re-establishes euvolemia
nd permits hospital discharge in 3 days without adverse
vents and prevents rehospitalization up to three months.
ETHODS
atient population. The subjects were consenting adult
DHF patients hospitalized for 12 h and given no
asoactive drugs and 1 dose of intravenous diuretic and
ith the following:
. Renal insufficiency or diuretic resistance (serum creati-
nine [sCr] 1.5 mg/dl, high daily oral diuretic doses
[furosemide 80 mg, torsemide 40 mg, or bumet-
amide 2 mg], or both) (2,4,11)
. Fluid overload, defined as 2 of the following:
a. Peripheral or sacral edema (2)
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c. Pulmonary rales, paroxysmal nocturnal dyspnea (PND),
or orthopnea
d. Jugular venous distention 7 cm
xclusion criteria were:
. Hematocrit 40%
. End-stage renal disease requiring dialysis
. Hypercoagulability
. SBP 85 mm Hg
. Requirement for intravenous inotropes
. Participation in another research study or previously in
this trial
tudy protocol. SCREENING PHASE. After screening and
nformed consent as approved by the participating hospitals’
nstitutional review boards, patients received physical exam-
nations, electrocardiography, global assessment (12), com-
lete blood count, blood chemistry, B-type natriuretic
eptide (BNP) level assessment (Triage BNP Test, Biosite,
an Diego, California) (13), partial thromboplastin time,
etermination of New York Heart Association functional
lass, and Minnesota Living With Heart Failure Question-
aire (MLWHFQ) (14). Estimated creatinine clearance
CrCl) was calculated using the Cockroft-Gault equation:
rCl (men) ([140 age] weight in kg)/(72 creatinine
n mg/dl);  0.85 for women (15).
RE-ULTRAFILTRATION PHASE. Heparin was administered
y standard protocols. Intravenous diuretics and vasodilators
ere avoided during ultrafiltration. Angiotensin-converting
nzyme inhibitors, angiotensin receptor blockers, beta-
lockers, aldosterone antagonists, nitrates, and digoxin were
ontinued.
LTRAFILTRATION PHASE. Weight and BNP levels were
easured at treatment initiation and completion. Blood
able 1. Clinical Signs and Symptoms of Volume Overload
Clinical Sign/Symptom Pre-UF, n (%) Discharg
eripheral edema 16 (80%) 13 (6
scites 19 (95%) 15 (7
ulmonary rales 13 (65%) 6 (3
aroxysmal nocturnal dyspnea 15 (75%) 8 (4
ugular venous distention 19 (95%) 17 (8
acral edema 7 (35%) 8 (4
Abbreviations and Acronyms
ADHERE  Acute Decompensated Heart Failure
National Registry
ADHF  acute decompensated heart failure
BNP  B-type natriuretic peptide
CrCl  creatinine clearance
MLWHFQ  Minnesota Living With Heart Failure
Questionnaire
SBP  systolic blood pressure
sCr  serum creatinineF  ultrafiltration.ressure and heart rate were recorded every 15 minutes for
n hour and then every hour. Physical examination and
lood chemistries were repeated at 2 and 24 h. After
annulation of the brachial-cephalic vein and standard
eparin priming, ultrafiltration was instituted at a maximum
ate of 500 cc/h. If SBP fell to 80 mm Hg, ultrafiltration
ate was reduced to 200 cc/h. Ultrafiltration was stopped
hen ADHF symptoms were resolved.
OLLOW-UP PHASE. Weights, complete blood count, chem-
stries, and examinations were obtained daily during hospi-
alization and at 30 and 90 days thereafter. The MLWHFQ
nd global assessment, medications, and rehospitalizations
ere recorded at 30 and 90 days. Medications were adjusted
y the treating physician.
tatistical analysis. Data are presented as mean values 
D. The clinical values obtained before initiation of ultra-
ltration were compared with those obtained after comple-
ion of therapy. Paired comparisons were performed using the
tudent t test for continuous variables and the McNemar test
or ordinal or categorical nonparametric values.
ESULTS
wenty patients were enrolled over six months. Seventy-five
atients were excluded owing to: 1) sCr 1.5 mg/dl and
ower-than-required diuretic doses (n 29); or 2) administra-
ion of 1 diuretic dose and/or vasoactive drugs (n  46).
Fifteen patients were male (75%) and 19 were Caucasian
95%). Age was 74.5  8.2 years (range 50.1 to 85.1 years).
eart failure was ischemic in 15 patients (75%) and non-
schemic in 5 patients. The left ventricular ejection fraction
as 31  15% (range 10% to 65%). Edema was present in
0% of patients, ascites in 95%, pulmonary rales in 65%,
ND in 75%, jugular venous distention in 95%, and sacral
dema in 35%. Ultrafiltration, initiated within 4.7  3.5 h
f hospitalization, removed 8,654  4,205 ml of fluid.
here were no failed venous cannulations, line malfunc-
ions, phlebitis, or thromboembolism.
Average hospitalization was 3.7  1.8 days. Twelve
atients (60%) were discharged in 3 days, four (20%) at
ay four, three (15%) at day five, and one (5%) at day 10.
mprovement of volume overload after ultrafiltration per-
isted at 30 and 90 days (Table 1). Values of the 20 patients
efore and after ultrafiltration and at 30 and 90 days are
hown in Table 2. Weights decreased from 87  23 kg to
(%) 30 Days, n (%) 90 Days, n (%) p Value
12 (63%) 7 (35%) 0.008
8 (40%) 9 (45%) 0.002
1 (5%) 4 (20%) 0.021
3 (15%) 4 (20%) 0.006
13 (65%) 6 (30%) 0.0005
1 (5%) 0 (0%) 0.031e, n
5%)
5%)
0%)
0%)
5%)
0%)
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t 30 (84  21 kg) and 90 days (80  18 kg); p  0.006
Fig. 1). Pre-ultrafiltration SBP was 120  17 mm Hg
range 99 to 172 mm Hg) and remained unchanged.
re-ultrafiltration sCr was 2.12  0.60 mg/dl (range 1.0 to
.6 mg/dl) and remained unchanged. Calculated CrCl was
7.9  13.4 ml/min and remained unchanged (Fig. 2).
lood urea nitrogen was 53  18 mg/dl (range 29 to 100
g/dl) and remained unchanged. Serum sodium (Na) was
36  4 mg/dl (range 128 to 142 mg/dl) and remained
igure 1. Average weights (Wt) (mean SD). *Pre-ultrafiltration (UF) to
0 days.
Table 2. Early Ultrafiltration Therapy: Clinica
Variable Pre-UF Disc
Weight (kg) 87  23 81
SBP (mm Hg) 120  17 114
BUN (mg/dl) 53  18 54
Cr (mg/dl) 2.12  0.6 2.20
Na (mg/dl) 136  4 137
K (mg/dl) 4.2  0.6 4.1
Hematocrit 35.3  3.8 35.9
Hemoglobin 11.5  1.3 11.6
Median BNP (pg/ml) 1,230 78
NYHA FC IV (%) 39 3
MLWHFQ 70  18 65
Global clinical status 5.7  1.3 1.8
BNP  B-type natriuretic peptide; BUN  blood urea nitro
Living With Heart Failure Questionnaire; Na  sodium; NY
systolic blood pressure; UF  ultrafiltration.igure 2. Average calculated creatinine clearance (CrCl) (mean  SD).
Pre-ultrafiltration (UF) to 90 days.
F
snchanged. In seven patients with serum Na 135 mg/dl,
a increased from pretreatment values at discharge (p 
.042) and at 90 days (p 0.017) (Fig. 3). Serum potassium
as 4.2  0.6 mg/dl (range 3.0 to 5.9 mg/dl) and remained
nchanged. Median BNP levels decreased after ultrafiltra-
ion (from 1,230 to 788 pg/ml) and remained lower at 30
ays (815 pg/ml) (p  0.035).
New York Heart Association functional class IV was
resent in seven patients (39%) before ultrafiltration, in one
igure 3. Average serum sodium (Na) for all 20 patients and for the seven
atients presenting with Na 135 mg/dl. *Pre-ultrafiltration (UF) to
ischarge; **pre-UF to 90 days.
Laboratory Outcomes
30 Days 90 Days p Value
84  21 80  18 0.006
120  26 116  24 0.306
59  23 58  28 0.219
2.38  1.1 2.18  0.7 0.532
137  3 137  2 0.475
4.1  0.6 4.2  0.6 0.646
35.3  4.3 37.0  4.7 0.270
11.5  1.6 12.2  1.4 0.095
815 NA 0.03
5 11 0.063
60  23 51  27 0.003
2.7  1.6 2.5  1.5 0.00003
r  creatinine; K  potassium; MLWHFQ  Minnesota
C  New York Heart Association functional class; SBP l and
harge
 22
 22
 20
 0.8
 3
 0.5
 4.1
 1.4
8
7
 21
 0.8
gen; Cigure 4. Average Minnesota Living With Heart Failure Questionnaire
cores (mean  SD). *Pre-ultrafiltration (UF) to 90 days.
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retreatment MLWHFQ score of 70  18 declined at
ischarge and 30 and 90 days to 65  21, 60  23.0, and
1  27, respectively (p  0.003) (Fig. 4). Global assess-
ent improved after ultrafiltration (from 5.7 1.3 to 1.8
.8) and remained improved at 30 (2.7  1.6) and 90 days
2.5  1.5) (p  0.00003) (Fig. 5).
In the three months preceding ultrafiltration, ten hospi-
alizations occurred in nine patients. After ultrafiltration,
ne patient was readmitted for ADHF within 30 days. Two
atients were readmitted between 30 and 90 days for
nrelated causes. Medications did not change significantly
or the 20 patients (Table 3).
ISCUSSION
arly ultrafiltration in patients with fluid overload and
iuretic resistance permitted the discharge of 60% of high-
isk ADHF patients in 3 days. Aggressive fluid with-
rawal (8,500 ml) with ultrafiltration was not associated
ith worsening renal failure, electrolyte abnormalities, or
ymptomatic hypotension. Early ultrafiltration was associ-
ted with a sustained drop in plasma BNP levels. Only one
atient was rehospitalized within 30 days. Compared with
he shorter hospitalizations reported here, in ADHERE the
verage hospitalization is 4.3 days and longer than six days
n patients with sCr 2 mg/dl (1). The economic conse-
uences of a shorter hospitalization were not directly calcu-
ated and are not reported in this study.
igure 5. Average global clinical assessment scores (mean  SD). *Pre-
ltrafiltration (UF) to 90 days.
Table 3. Number and Percentage of Patients R
Drug Class Pre-UF, n (%) Discharge,
Loop diuretic 15 (75) 20 (100
Thiazide diuretic 4 (20) 6 (30)
ACEI 9 (45) 9 (45)
ARB 1 (0.5) 2 (10)
Beta-blocker 10 (50) 11 (55)
Nitrates 8 (40) 7 (35)
Digoxin 7 (35) 7 (35)ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotRenal insufficiency and diuretic resistance in ADHF
ortend poorer outcomes and higher costs (1,4,11). The
tudy patients had both renal insufficiency and diuretic
esistance, as documented by congestion despite chronic
iuretics (2,4,5,11). These are the patients most likely to
eceive intravenous diuretics, which acutely increase neuro-
ormonal activation and decrease glomerular filtration rate
9). In contrast, in the study population, ultrafiltration
ecreased neurohormonal activation, as indicated by the
rop in plasma BNP levels without worsening renal func-
ion (9). These findings are consistent with previous obser-
ations that plasma norepinephrine, renin, and aldosterone
evels drop with ultrafiltration but not with intravenous
iuretics (9). The discharge BNP levels of 400 pg/ml may
e due to the severe renal dysfunction.
Whereas nine patients required hospitalization for
DHF in the three months preceding ultrafiltration, only
ne patient required hospitalization for ADHF in the three
onths after treatment. Similarly, in a previous study,
linical improvements following ultrafiltration persisted for
hree months (9).
Reversal of the braking phenomenon by diuretic holiday
r reduced neurohormonal activation by ultrafiltration may
xplain improved diuresis and natriuresis (2,9).
Continued improvement for three months after ultrafil-
ration, without significant medication changes, suggests
hat ultrafiltration improved natriuresis and diuresis. Nor-
alization of serum Na in the seven hyponatremic patients
uggests that ultrafiltration may be valuable for patients with
olume overload and hyponatremia.
In summary, the study documents that early ultrafiltra-
ion safely and effectively reduces congestion in ADHF with
iuretic resistance. A treatment strategy of early ultrafiltra-
ion may decrease length of stay and rehospitalizations in
igh-risk heart failure patients. Clinical benefits of early
ltrafiltration last at least three months. Thus, early ultra-
ltration maybe an alternative to reserving ultrafiltration for
atients refractory to all other pharmacologic strategies. In
his pilot study the reduction in hospitalization may be due
o the combined benefits of ultrafiltration and highly struc-
ured continuing care. A prospective randomized study
omparing ultrafiltration with standard therapy for ADHF
s ongoing to identify effects specifically attributable to
ltrafiltration.
ing Drug
30 Days, n (%) 90 Days, n (%) p Value
17 (85) 19 (95) 0.219
5 (25) 5 (25) 1.000
10 (50) 11 (55) 0.687
2 (10) 3 (15) 0.500
9 (45) 12 (60) 0.375
6 (30) 9 (45) 0.625
6 (30) 6 (30) 1.000eceiv
n (%)
)ensin receptor blocker; UF  ultrafiltration.
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